All In Biotech

Drugs by condition

Drugs approved for acute lymphoblastic leukemia

Brand-name prescription drugs and biologics whose FDA label lists acute lymphoblastic leukemia as an approved use. Matched on the label phrases: "acute lymphoblastic leukemia".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

19

Still marketed, NDA or BLA

Drug classes

6

Novel drugs

9

New molecular entities and new biologics

In development

9

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for acute lymphoblastic leukemia.

  • Oxderys (Doxorubicin Hydrochloride) · Avyxa Holdings Nov 9, 2026
  • Imkeldi (Imatinib Mesylate) · Shorla Oncology Nov 22, 2024
  • Phyrago (Dasatinib) · Handa Therap OrphanDec 5, 2023
  • Jylamvo (Methotrexate) · Shorla Nov 29, 2022
  • Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) · Jazz Pharms NovelOrphanJun 30, 2021

All approved drugs for acute lymphoblastic leukemia, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 66 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Asparagine-specific Enzyme (3)

  • Rylaze Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn · Jazz Pharms · 2021
  • Asparlas Calaspargase Pegol-Mknl · Servier Pharma LLC · 2018
  • Oncaspar Pegaspargase · Sigma Tau · 1994

Folate Analog Metabolic Inhibitor (2)

  • Jylamvo Methotrexate · Shorla · 2022
  • Xatmep Methotrexate Sodium · Azurity · 2017

CD22-directed Immunoconjugate (1)

  • Besponsa Inotuzumab Ozogamicin · Wyeth Pharms INC · 2017

Nucleoside Metabolic Inhibitor (1)

  • Arranon Nelarabine · Sandoz · 2005

Leukocyte Growth Factor (1)

  • Leukine Sargramostim · Berlex Labs · 1991

Class not listed in FDA's data (11)

Drugs in development for acute lymphoblastic leukemia

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • SurovatamigAZD0486, TNB-486Phase 39 trials

    AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • RimiducidAP1903Phase 23 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

  • single CNCT19Phase 23 trials

    Juventas Cell Therapy Ltd. · Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma

  • rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

  • YK012Phase 22 trials

    Excyte Biopharma Ltd · Systemic Lupus Erythematosus (SLE), B-cell Acute Lymphoblastic Leukemia

  • TGRX-814Phase 21 trial

    Shenzhen TargetRx Co., Ltd. · Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia

  • UCART22Phase 21 trial

    Cellectis S.A. · B-cell Acute Lymphoblastic Leukemia

More on acute lymphoblastic leukemia: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.